ASC30: Ascletis GLP-1 Pill Results, Phase 3 and FDA Status
ASC30 is an experimental once-daily GLP-1 pill for weight loss made by Ascletis Pharma. It is not FDA-approved and you cannot buy it. In a 13-week US phase 2 study, the top dose led to 7.7% more weight loss than placebo, and two phase 3 trials (AURORA-1 and AURORA-2) with about 4,600 people are now running, with results expected in late 2028. On November 11, 2026, Ascletis also asked the FDA for permission to start human testing of ASC30_39, a pill that pairs ASC30 with an amylin drug. Any pill that takes weight off this fast can take muscle with it, so a daily protein target and a short strength workout matter; Sharpy gives you both.
What is ASC30, and can you get it yet? ASC30 is an experimental once-daily GLP-1 pill for weight loss from Ascletis Pharma. You cannot get it yet. It is in phase 3 trials, it is not FDA-approved, and the company does not expect its big trial results until the third quarter of 2028.
It is in the news today because of a second pill built on top of it. On November 11, 2026, Ascletis said it had sent the FDA an application to begin human testing of ASC30_39, a single tablet that combines ASC30 with an amylin drug. Here is what is known about both, in plain English.
ASC30 at a glance
| ASC30 | |
|---|---|
| Maker | Ascletis Pharma (Hong Kong listed, HKEX: 1672) |
| Type of drug | Small-molecule GLP-1 receptor agonist |
| Forms in testing | Once-daily tablet, once-monthly injection |
| Stage | Tablet: phase 3. Monthly injection: phase 2 |
| Phase 2 tablet result | Up to 7.7% placebo-adjusted weight loss at 13 weeks |
| Phase 3 trials | AURORA-1 and AURORA-2, about 4,600 adults, 72 weeks |
| Phase 3 results expected | Third quarter of 2028 |
| FDA approved? | No |
| Price | None. It is not for sale |
ASC30 mechanism of action: how the pill works
ASC30 turns on the GLP-1 receptor, the same target as Ozempic, Wegovy and Foundayo. That slows the stomach, lowers appetite and helps control blood sugar.
The difference is the kind of molecule. Semaglutide is a peptide, a small protein that the stomach breaks down. ASC30 is a "small molecule," a simple chemical that survives digestion. Foundayo (orforglipron) is the same kind of drug. Ascletis describes ASC30 as a "biased" GLP-1 agonist that it discovered in-house. The company has not shown in people that this design leads to better results than other GLP-1 drugs.
ASC30 phase 2 results: weight loss at 13 weeks
Ascletis reported topline results on December 8, 2025, from a US study (NCT07002905). It enrolled 125 adults with obesity, or overweight plus at least one weight-related health problem. The average starting weight was 107.3 kg (about 237 pounds).
| Daily dose | Extra weight loss vs placebo at week 13 | Stopped because of side effects |
|---|---|---|
| 20 mg | 5.4% | 7.3% |
| 40 mg | 7.0% | 7.5% |
| 60 mg | 7.7% | 0% |
| Placebo | (comparison group) | 0% |
Three things to keep in mind:
- It was short. Thirteen weeks is early. GLP-1 weight loss usually keeps going for a year or more.
- It was small. 125 people were split across several groups.
- It is a company release. The full data have not appeared in a peer-reviewed journal that we could find.
ASC30 nausea and other side effects
Side effects were the usual GLP-1 kind: nausea, vomiting and constipation. Overall, 4.8% of participants stopped because of side effects, and every one of those stops was for a stomach or gut problem. Ascletis reported no severe (grade 3 or higher) gut side effects, no drug-related serious side effects and no signs of liver harm.
The company also says vomiting was about half the rate seen with orforglipron when both drugs were stepped up every week. Be careful with that claim. It compares two separate studies with different people, which is not the same as testing the two pills side by side. In phase 3, the dose is raised more slowly, over 12 to 20 weeks.
ASC30 phase 3: the AURORA trials
The FDA cleared ASC30 for phase 3, and Ascletis announced the start on August 3, 2026. Both trials are listed as recruiting on ClinicalTrials.gov.
| AURORA-1 | AURORA-2 | |
|---|---|---|
| ClinicalTrials.gov ID | NCT07743463 | NCT07743450 |
| Who | Obesity or overweight, no type 2 diabetes | Obesity or overweight with type 2 diabetes |
| Planned size | 3,003 adults | 1,560 adults |
| Doses | 20, 40 or 60 mg once a day, or placebo | Same |
| Length | 72 weeks | 72 weeks |
| Main measure | Percent change in body weight | Percent change in body weight |
The trials are running in the US, Canada and Europe. Ascletis expects topline results in the third quarter of 2028, a US approval filing by the end of 2028 and a European filing in early 2029. Those are company plans, and trial timelines often slip.
ASC30_39: the new GLP-1 plus amylin pill
Amylin is a second fullness hormone. Drug makers are pairing it with GLP-1 to try to get more weight loss. So far, the amylin drugs in late testing are shots, like petrelintide and Lilly's eloralintide.
ASC30_39 is Ascletis's attempt to put both in one daily tablet: ASC30 plus ASC39, a small-molecule amylin receptor agonist. Here is what the November 11, 2026 release says:
- Ascletis submitted an IND application to the FDA. The company has not said that the FDA has cleared it, and it gave no start date for the first human study.
- In dogs, the combination tablet had a half-life of up to 12 hours.
- In obese rats, ASC39 alone led to 6.6% placebo-adjusted weight loss after six days, which the company called similar to eloralintide at 5.6%.
- In an earlier monkey study, the combination led to 6.9% weight loss in seven days.
All of that is animal data. Animal results often do not carry over to people, and no human has taken ASC30_39 in a trial yet.
ASC30 once-monthly injection
Ascletis is also testing ASC30 as a long-acting shot. In a US phase 2 study of 65 adults reported on March 10, 2026, three monthly 400 mg doses of one formulation led to 6.3% placebo-adjusted weight loss at week 12 and 7.5% at week 16. No one stopped because of side effects. The company reported a half-life of 46 to 75 days from an earlier study. A second formulation did not reach useful drug levels. For another monthly option in testing, see our MariTide guide. Innogen's efsubaglutide alfa, a long-acting GLP-1 shot approved in China for diabetes, is also being tested with once-a-month dosing.
ASC30 vs Foundayo and the Wegovy pill
| ASC30 | Foundayo (orforglipron) | Wegovy pill | |
|---|---|---|---|
| Maker | Ascletis | Eli Lilly | Novo Nordisk |
| Type | Small molecule | Small molecule | Peptide (semaglutide) |
| FDA status | Phase 3 | Approved April 2026 | Approved December 2025 |
| Longest weight-loss data | 13 weeks | 72 weeks | 64 weeks |
| Average result in that study | 7.7% vs placebo (top dose) | 11.1% (top dose) | 13.6% |
You cannot rank these from the table. A 13-week number and a 72-week number measure different things. If you want a GLP-1 pill today, the two approved choices are covered in our Foundayo guide and our Wegovy pill vs Foundayo comparison. If you are weighing a pill against an injection, see GLP-1 pill vs shot.
Does ASC30 protect muscle?
There is no data on that. Ascletis has not published body composition results for ASC30. With approved GLP-1 drugs, part of the weight lost is lean mass, which includes muscle. There is no reason to assume a new pill will be different.
What protects muscle is the same on every drug: enough protein and regular strength training. Sharpy turns that into one protein target and one 20-minute workout a day, with a Shape Score to show if you are losing fat and keeping muscle. Our protein target guide explains how the number is set.
Can you buy ASC30 tablets?
No. ASC30 is only available inside clinical trials. Any website selling "ASC30" is selling an unapproved product with no proof of what is in it. If you want to take part in a trial, search the NCT numbers above on ClinicalTrials.gov and talk with your doctor about whether it fits you.
The bottom line
ASC30 is an early but real contender among GLP-1 pills. Its short phase 2 study showed up to 7.7% more weight loss than placebo in 13 weeks, and two large phase 3 trials are under way with results due in 2028. Today's news, the ASC30_39 combination with amylin, is one step earlier still: an FDA application, backed by animal data only. Nothing here changes what you can be prescribed today. Whatever you take, eat enough protein and train your muscles. Sharpy keeps both on track in a few minutes a day.
Sources
- Ascletis: IND submission for ASC30_39 FDC, press release (November 11, 2026)
- Ascletis: Initiation of global phase 3 for ASC30, press release (August 3, 2026)
- ClinicalTrials.gov: AURORA-1, NCT07743463
- ClinicalTrials.gov: AURORA-2, NCT07743450
- ClinicalTrials.gov: ASC30 13-week phase 2 study, NCT07002905
- Ascletis: 13-week phase 2 topline results for ASC30 tablets (December 8, 2025), as carried by Tiger Brokers
- Ascletis: Phase 2 topline results for once-monthly ASC30 (March 10, 2026), as carried by Tiger Brokers
Questions people ask
What is ASC30?
ASC30 is an investigational small-molecule GLP-1 receptor agonist from Ascletis Pharma, a company listed in Hong Kong (HKEX: 1672). It is being tested as a once-daily tablet for obesity and overweight, and also as a once-monthly injection. It is not approved anywhere.
Is ASC30 FDA approved?
No. As of November 11, 2026, ASC30 is in phase 3 trials. Ascletis says it expects topline phase 3 results in the third quarter of 2028 and plans to file for US approval by the end of 2028. Approval, if it comes, would be after that.
How much weight do people lose on ASC30 tablets?
In the 13-week US phase 2 study of 125 adults, placebo-adjusted weight loss was 5.4% at 20 mg, 7.0% at 40 mg and 7.7% at 60 mg. These are company topline numbers from a short study. The 72-week phase 3 trials will show the longer-term result.
Does ASC30 cause nausea and vomiting?
Yes, stomach side effects were the main ones. In phase 2, 4.8% of participants stopped because of side effects, all from nausea, vomiting or constipation. Ascletis says vomiting was about half the rate seen with orforglipron under weekly dose increases, but that compares two separate studies, not a head-to-head trial.
What is ASC30_39?
ASC30_39 is a once-daily combination tablet that puts ASC30 together with ASC39, a small-molecule amylin receptor agonist. Ascletis submitted an Investigational New Drug (IND) application for it to the FDA on November 11, 2026. It has only been tested in animals so far.
What is the ASC30 phase 3 trial?
There are two: AURORA-1 (NCT07743463) in adults with obesity or overweight without type 2 diabetes, and AURORA-2 (NCT07743450) in adults who also have type 2 diabetes. Both run 72 weeks and test 20 mg, 40 mg and 60 mg once a day against placebo.
How is ASC30 different from Foundayo?
Both are once-daily small-molecule GLP-1 pills, not peptides like semaglutide. Foundayo (orforglipron) from Eli Lilly is FDA-approved and on sale. ASC30 is still in trials. They have never been tested against each other.